| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $311,460 across 3 awards. 36C26024F0173 PHARMACEUTICAL; 36C26025F0002 HETLIOZ - BULK; 36C26026F0025 PHARM - HETLIOZ | Qwen corrected direction:… |
| SPECIALTY-PHARMACIES |
SPECIALTY-PHARMACIES |
92%
|
The Company invoices and records revenue when its customers, wholesalers, specialty pharmacies and specialty distributors, receive product from the third-party logistics warehouse, which is the point… |
| NOVARTIS-PHARMA-AG |
NOVARTIS-PHARMA-AG |
85%
|
ffectively would materially harm our business. • Our revenues from Fanapt ® and PONVORY ® are substantially dependent on sales through a limited number of customers. • We face substantial competition… |
| JNJ |
Johnson & Johnson |
72%
|
ash paid to Janssen and acquisition-related transaction costs. The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering los… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from VNDA graph: ash paid to Janssen and acquisition-related transaction costs. The Purchase Agreement includes customary representatio… |
| LLY |
Eli Lilly and Company |
72%
|
period of up to 10 years in markets where the new chemical entity (NCE) patent has expired or was not issued. We are obligated to pay this 6% royalty on net sales in the U.S. through November 2026. N… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from VNDA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VNDA graph: period of up to 10 years in markets w… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from VNDA graph: Reciprocal relationship from MRK graph: Reciprocal relationship from VNDA graph: Reciprocal relationship from MRK grap… |
| MRK |
Merck & Co., Inc. |
72%
|
he U.S. in April 2014 and the oral suspension (HETLIOZ LQ ® ) in March 2021. Additionally, HETLIOZ ® capsules were approved in the E.U. for the treatment of Non-24 in totally blind adults in July 201… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from VNDA graph: . Intangible assets are amortized over their estimated useful economic life using the straight-line method. $ $ PONV… |
| SNYNF |
Sanofi |
72%
|
. Intangible assets are amortized over their estimated useful economic life using the straight-line method. $ $ PONVORY ® NEREUS TM Total amortization expense $ $ $ $ $ $ $ $ $ PONVORY ® NEREUS TM To… |
| ACTELION-PHARMACEUTICALS-LTD |
ACTELION-PHARMACEUTICALS-LTD |
62%
|
ult in a reduction in the demand for HETLIOZ ® and/or the price at which we can sell it and/or create volatility in net product sales in future periods, which would have a material and adverse impact… |
| INTRA-CELLULAR-THERAPIES-INC |
INTRA-CELLULAR-THERAPIES-INC |
62%
|
he U.S. in April 2014 and the oral suspension (HETLIOZ LQ ® ) in March 2021. Additionally, HETLIOZ ® capsules were approved in the E.U. for the treatment of Non-24 in totally blind adults in July 201… |
| LUNDBECK-OTSUKA-AMERICA-PHARMACEUTICAL-INC |
LUNDBECK-OTSUKA-AMERICA-PHARMACEUTICAL-INC |
62%
|
he U.S. in April 2014 and the oral suspension (HETLIOZ LQ ® ) in March 2021. Additionally, HETLIOZ ® capsules were approved in the E.U. for the treatment of Non-24 in totally blind adults in July 201… |
| OTSUKA-AMERICA-PHARMACEUTICAL-INC |
OTSUKA-AMERICA-PHARMACEUTICAL-INC |
62%
|
he U.S. in April 2014 and the oral suspension (HETLIOZ LQ ® ) in March 2021. Additionally, HETLIOZ ® capsules were approved in the E.U. for the treatment of Non-24 in totally blind adults in July 201… |
| PATHEON-PHARMACEUTICALS-INC |
PATHEON-PHARMACEUTICALS-INC |
62%
|
nical trials successfully or have difficulty enrolling a sufficient number of patients for them, we may not receive the regulatory approvals needed to market that product. Any such failure or difficu… |
| PRESENTATION-BUSINESS-ORGANIZATION-VANDA-PHARMAC |
PRESENTATION-BUSINESS-ORGANIZATION-VANDA-PHARMAC |
62%
|
ommunicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, … |
| SOUTH-CAROLINA-GENESIS-HEALTH-CARE-INC |
SOUTH-CAROLINA-GENESIS-HEALTH-CARE-INC |
62%
|
oducts, thereby reducing our future earnings and prospects. A loss or disruption with any one of our manufacturers or suppliers could disrupt the supply of Fanapt ® , HETLIOZ ® , HETLIOZ LQ ® or PONV… |
| SUNOVION-PHARMACEUTICALS-INC |
SUNOVION-PHARMACEUTICALS-INC |
62%
|
he U.S. in April 2014 and the oral suspension (HETLIOZ LQ ® ) in March 2021. Additionally, HETLIOZ ® capsules were approved in the E.U. for the treatment of Non-24 in totally blind adults in July 201… |
